免疫检查点抑制剂在非小细胞肺癌治疗中的应用

被引：4

作者：

袁连方

蔡琦玲

邵娜

机构：

[1] 天津市南开医院呼吸内科

来源：

继续医学教育 | 2017年 / 31卷 / 01期

关键词：

非小细胞肺癌; 免疫检查点抑制剂; 程序性细胞死亡蛋白; 程序性细胞死亡蛋白配体; 细胞毒性T淋巴细胞相关抗原-4;

D O I：

暂无

中图分类号：

R734.2 [肺肿瘤];

学科分类号：

100214 ;

摘要：

近年来,非小细胞肺癌的预后仍较差,而免疫检查点抑制剂已成为肿瘤免疫治疗的一大热点。目前关于程序性细胞死亡蛋白(programmed cell death-1,PD-1)及其配体(programmed cell death ligand 1,PD-L1)、细胞毒性T淋巴细胞相关抗原-4(cytotoxic T lymphocyte associated antigen 4,CTLA-4)等通路抑制剂在非小细胞肺癌中开展了相关研究,且FDA批准一种PD-1抑制剂用于非小细胞肺癌的二线治疗,前景较为乐观。针对免疫检查点抑制剂在非小细胞肺癌中的应用作论述。

引用

页码：125 / 128

页数：4

共 23 条

[1]

Combining radiation and immunotherapy:a new systemic therapy for solid tumors. Tang C,Wang X,Soh H,Seyedin S,Cortez MA,Krishnan S,Massarelli E,Hong D,Naing A,Diab A,Gomez D,Ye H,Heymach J,Komaki R,Allison JP,Sharma P,Welsh JW. Cancer Immunol Res . 2014

[2]

The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Gooden M J M,de Bock G H,Leffers N,Daemen T,Nijman H W. British Journal of Cancer . 2011

[3] New driver mutations in non-small-cell lung cancer [J].

Pao, William ;

Girard, Nicolas .

LANCET ONCOLOGY, 2011, 12 (02) :175-180

[4]

Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study[J] . Thomas J. Lynch,Igor Bondarenko,Alexander Luft,Piotr Serwatowski,Fabrice Barlesi,Raju Chacko,Martin Sebastian,Joel Neal,Haolan Lu,Jean-Marie Cuillerot,Martin Reck. &nbspJournal of Clinical Oncology . 2012 (17)

[5]

Cancer statistics in China, 2015[J] . Wanqing Chen,Rongshou Zheng,Peter D. Baade,Siwei Zhang,Hongmei Zeng,Freddie Bray,Ahmedin Jemal,Xue Qin Yu,Jie He. &nbspCA: A Cancer Journal for Clinicians . 2016 (2)

[6]

Safety and Clinical Activity of MK-3475 as Initial Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)[J] . A.S. Balmanoukian,N.A. Rizvi,E.B. Garon,A. Patnaik,L. Gandhi,N.B. Leighl,J.W. Goldman,J.P. Eder,E.A. Johnson,G.R. Blumenschein,M.A. Gubens,K.P. Papadopoulos,G.M. Lubiniecki,J. Zhang,M. Niewood,K. Emancipator,M. Dolled-Filhart,M.E. Hanson,R. Hui. &nbspInternational Journal of Radiation Oncology, Biology, Physics . 2014 (5)

[7]

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. Freeman GJ,Long AJ,Iwai Y,et al. Journal of Experimental Medicine, The . 2000

[8]

Tissue expression of PD-L1 mediates peripheral T cell tolerance. Keir Mary E,Liang Spencer C,Guleria Indira,Latchman Yvette E,Qipo Andi,Albacker Lee A,Koulmanda Maria,Freeman Gordon J,Sayegh Mohamed H,Sharpe Arlene H. The Journal of experimental medicine . 2006

[9]

IMMUNOLOGY[P]. BOZICEVICH JOHN.中国专利:US3449488A,1969-06-10

[10]

CD28 and CTLA-4 coreceptor expression and signal transduction. Rudd Christopher E,Taylor Alison,Schneider Helga. Immunological Reviews . 2009

← 1 2 3 →